1-3 of 3
Sritama Nath
Close
Sort by
Journal Articles

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Nirali N. Shah, Jacques Azzi, Brenda W Cooper, Abhinav Deol, John DiPersio, Divya Koura, Brian McClune, Lori S. Muffly, Muhammad Umair Mushtaq, Rupa Narayan, Hyung Chan Suh, Gregory Yanik, Sritama Nath, Jennifer Whangbo, Guenther Koehne
Journal: Blood
Blood (2023) 142 (Supplement 1): 4862.
https://doi.org/10.1182/blood-2023-180990
Published: 2023
Journal Articles

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, Michael R. Loken, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne
Journal: Blood
Blood (2023) 142 (Supplement 1): 483.
https://doi.org/10.1182/blood-2023-190037
Published: 2023
Journal Articles

Trial in Progress: A First-in-Human Phase 1/2 Study of Hematopoietic Stem Cell Transplantation (HCT) with VOR33 (CD33-Deleted Allograft) Followed By Treatment with Gemtuzumab Ozogamicin (GO) in Patients with CD33+ Acute Myeloid Leukemia (AML) Who Are at High-Risk of Post-HCT Relapse

Brenda W. Cooper, Hyung C. Suh, Divya Koura, Guenther Koehne, Christina Cho, Nadia M. Bambace, Léa Bernard, Nirali N. Shah, Roland B. Walter, John F. DiPersio, Sritama Nath, Melissa M. Lee-Sundlov, Ali Lacy, Darren Stanizzi, Karen Kuhn, Jennifer S. Whangbo, Christopher Slapak, Glen D. Raffel
Journal: Blood
Blood (2022) 140 (Supplement 1): 12973–12975.
https://doi.org/10.1182/blood-2022-165289
Published: 2022